Abstract: Modern embedded systems are evolving quickly, demanding innovative approaches to software development across various domains. Selecting the right programming language is crucial for ...
Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages Akari's proprietary PH1 spliceosome payload and a novel antibody construct ...
New pipeline candidate AKTX-102 leverages Akari’s proprietary PH1 spliceosome payload and a novel antibody construct to address one of oncology’s most challenging and valuable solid tumor targets, ...
Abstract: This paper describes a low-power voice-activated prototype providing a hands-free user interface for voice commands. Utilizing a microelectromechanical-system microphone, the device extracts ...
TAMPA and LONDON, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company pioneering next-generation antibody drug conjugates (ADCs) powered by ...